Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $7.0700 (-0.98%) ($6.9300 - $7.1400) on Fri. Nov. 20, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.42% (three month average) | RSI | 17 | Latest Price | $7.0700(-0.98%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -1% a day on average for past five trading days. | Weekly Trend | HTBX declines -6.4% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) XBI(34%) ARKG(33%) ARKK(33%) BLOK(32%) IBB(31%) | Factors Impacting HTBX price | HTBX will decline at least -2.71% in a week (0% probabilities). VXX(-21%) VIXM(-21%) UUP(-15%) XLU(-3%) XLP(-3%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.71% (StdDev 5.42%) | Hourly BBV | 0.2 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-5.21(-173.69%) | Resistance Level | $7.7 | 5 Day Moving Average | $7.17(-1.39%) | 10 Day Moving Average | $7.24(-2.35%) | 20 Day Moving Average | $7.7(-8.18%) | To recent high | -28.4% | To recent low | 0% | Market Cap | $778m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |